Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. (Q52728078)

2 July 2018

title

Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia. (English)

1 reference

2 July 2018

author name string

Jessica C Petrov

1

1 reference

2 July 2018

Masayuki Wada

2

1 reference

2 July 2018

Kevin G Pinz

3

1 reference

2 July 2018

Lulu E Yan

4

1 reference

2 July 2018

Kevin H Chen

5

1 reference

2 July 2018

Xiao Shuai

6

1 reference

2 July 2018

Hua Liu

7

1 reference

2 July 2018

Xi Chen

8

1 reference

2 July 2018

Lai-Han Leung

9

1 reference

2 July 2018

Huda Salman

10

1 reference

2 July 2018

Nabil Hagag

11

1 reference

2 July 2018

Fang Liu

12

1 reference

2 July 2018

Xun Jiang

13

1 reference

2 July 2018

Yupo Ma

14

1 reference

2 July 2018

publication date

25 February 2018

1 reference

2 July 2018

published in

Leukemia

1 reference

2 July 2018

volume

32

1 reference

2 July 2018

issue

6

1 reference

2 July 2018

page(s)

1317-1326

1 reference

2 July 2018

Creative Commons Attribution 4.0 International

copyright license

start time

25 February 2018

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Recent developments in immunotherapy of acute myeloid leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

CD33, CD96 and Death Associated Protein Kinase (DAPK) Expression Are Associated with the Survival Rate and/or Response to the Chemotherapy in the Patients with Acute Myeloid Leukemia (AML).

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Treatment of Relapsed/Refractory Acute Myeloid Leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Preclinical targeting of aggressive T-cell malignancies using anti-CD5 chimeric antigen receptor.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Preclinical targeting of human T-cell malignancies using CD4-specific chimeric antigen receptor (CAR)-engineered T cells.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

A T-cell-directed chimeric antigen receptor for the selective treatment of T-cell malignancies

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Anti-CD33 chimeric antigen receptor targeting of acute myeloid leukemia.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

CD123 and its potential clinical application in leukemias.

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Treatment of CD33-directed chimeric antigen receptor-modified T cells in one patient with relapsed and refractory acute myeloid leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Recent advances in acute myeloid leukemia stem cell biology

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

A compound chimeric antigen receptor strategy for targeting multiple myeloma

3 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Emerging treatments in acute myeloid leukemia: current standards and unmet challenges

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Chimeric antigen receptor T-cell therapies for multiple myeloma

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Aberrant expression of CD123 (interleukin-3 receptor-α) on neoplastic mast cells.

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts

13 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5990523

Differences in CD33 intensity between various myeloid neoplasms

13 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FS41375-018-0075-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Persistence of CD33 expression at relapse in CD33(+) acute myeloid leukaemia patients after receiving Gemtuzumab in the course of the disease

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FS41375-018-0075-3

inferred from DOI database lookup

7 January 2021

based on heuristic

Interleukin-3 receptor alpha chain (CD123) is widely expressed in hematologic malignancies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/29515236

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/S41375-018-0075-3

1 reference

2 July 2018

PMC publication ID

5990523

1 reference

2 July 2018

PubMed publication ID

29515236

1 reference

2 July 2018